Shanxi Teamgene Biological announced that it will receive CNY 50,000,000 in a round of funding on March 30, 2023. The transaction included participation from returning investor Shandong Teamgene Technology Co., Ltd. After the capital increase, company's registered capital will increase from CNY 115,000,000 to CNY 165,000,000 still the company's wholly-owned subsidiary. The transaction has been approved in the 13th session of the company's 1st directorate and the 11th session of the company's 1st supervisory board approved.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12.18 CNY | -2.25% | -1.62% | -19.28% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-19.28% | 289M | |
+9.40% | 11.17B | |
+0.54% | 6.09B | |
+1.49% | 5.21B | |
+13.27% | 5B | |
-27.85% | 2.52B | |
+1.45% | 1.92B | |
-19.20% | 1.27B | |
+45.11% | 1B | |
-21.85% | 850M |
- Stock Market
- Equities
- 603151 Stock
- News Shandong Teamgene Technology Co., Ltd.
- Shanxi Teamgene Biological announced that it expects to receive CNY 50 million in funding from Shandong Teamgene Technology Co., Ltd.